TABLE 4.

Organ colony counts from a series of experiments

Expt no.bGroupDose (mg/kg)Colony count (mean log10 CFU/g ± SD)a
AMBMycograbKidneyLiverSpleen
110.62(9)e(9)d(9)d
20.60.2(10)e(10)d(9)d
30.6b3.66 ± 0.82 (4)(9)d(10)d
42b4.58 ± 0.76 (2)b3.50 ± 0.47 (3)b3.12 ± 0.11 (4)
50.25.1 ± 0.11 (0)3.85 ± 0.81 (3)3.35 ± 0.33 (3)
65.5 ± 0.5 (0)4.42 ± 0.59 (2)3.65 ± 0.69 (2)
210.62(9)d(9)d(8)d,e
20.60.2(9)d(8)d3.71 ± 0.64 (4)
30.6(9)d(7)b4.18 ± 0.22 (2)
42(6)b4.32 ± 0.82 (4)b3.87 ± 0.93 (1)
50.2(6)b4.35 ± 0.26 (4)b3.81 ± 0.78 (1)
64.05 ± 0.1 (0)5.15 ± 0.18 (0)4.81 ± 0.33 (0)
310.62(9)d(6)(8)d,e
20.60.2(10)d(6)(8)d,e
30.6(9)db4.74 ± 1.0 (2)b4.24 ± 0.25 (3)
42(8)db5.54 ± 0.18 (0)b5.19 ± 0.31 (0)
50.25.17 ± 0.19 (2)b6.01 ± 0.25 (0)5.30 ± 0.39 (0)
65.19 ± 0.90 (0)6.57 ± 0.34 (0)5.86 ± 0.76 (0)
410.62(8)d(10)d(10)d
20.60.2(8)d(10)d(10)d
30.6(8)d(10)d(10)d
42b4.24 ± 0.95 (1)(9)d(10)d
50.2b4.41 ± 0.72 (1)(10)d(10)d
65.30 ± 0.13 (0)3.82 ± 0.69 (1)4.41 ± 0.93 (3)
510.623.82 ± 0.81 (4)(10)d,e(10)d,e
20.60.23.84 ± 0.78 (1)(9)d3.89 ± 0.94 (2)
30.64.01 ± 0.93 (1)3.08 ± 0.12 (5)4.10 ± 0.98 (0)
424.01 ± 0.92 (1)(9)d4.03 ± 0.33 (2)
50.24.01 ± 0.09 (3)(9)d4.07 ± 0.31 (3)
64.00 ± 0.04 (0)3.54 ± 0.65 (3)4.05 ± 0.08 (0)
610.62b4.56 ± 0.81 (0)b3.66 ± 0.25 (4)b4.08 ± 0.02 (2)
20.60.2b4.48 ± 0.34 (0)b4.09 ± 0.27 (2)b4.11 ± 0.29 (1)
30.6b4.62 ± 0.94 (0)b3.98 ± 0.06 (3)b4.24 ± 0.29 (2)
42b4.60 ± 0.65 (0)b4.07 ± 0.26 (3)b4.32 ± 0.31 (1)
50.2b4.77 ± 0.79 (0)b4.28 ± 0.28 (0)b4.48 ± 0.38 (2)
65.66 ± 0.64 (0)5.31 ± 0.44 (0)5.24 ± 0.16 (0)
  • a Number of negative biopsy specimen in parentheses.

  • b Experiments: 1, FLC-resistant C. albicans; 2, C. krusei; 3, C. glabrata 4, C. tropicalis; 5, C. parapsilosis; 6, C. parapsilosis (clinical isolate).

  • c Statistically significant (Scheffe's test, P < 0.05) versus the control group 6.

  • d Statistically significant number of negative biopsy specimens (Fisher's exact test, P < 0.05) versus the control group 6.

  • e Statistically significant numbers of negative biopsy specimens (Fisher's exact test, P < 0.05) versus the AMB-treated group 3.